Abstract:525 Objectives The mesenchymal epithelial transition (c-Met) factor overexpression has been widely accepted as a potent biomarker for various of cancers such as glioblastoma, breast cancer, colorectal cancer, etc. c-Met inhibitor, which targets c-Met and further interferes with downstream signaling pathways, could serve as both diagnostic and therapeutic molecule by specifically binding with c-Met receptors. Until now small molecule based probes for c-Met imaging has not been reported. In previous studies, we have successfully synthesized c-Met inhibitor C21b with high c-Met receptor binding and suppressing functions and validated its tumor suppression capability. In the present study, we aim to develop a 68Ga labeled, C21b based PET probe for imaging of c-Met positive tumors such as glioblastoma which realize the potential for both glioblastoma detection and cancer therapy evaluation. Methods C21b molecule with NODAGA chelator was obtained through chemical synthesis and confirmed by MS and 1H-NMR. The resulting conjugate NODAGA-C21b was radiolabeled with 68Ga in 0.1N sodium acetate (pH 5.5) at 55 oC within 15 min. The PET probe was then characterized by HPLC analysis and subjected to mouse serum stability assay. The cell uptake and binding affinity tests of 68Ga-NODAGA-C21b were conducted using U87MG glioblastoma cells. Small animal PET imaging and biodistribution analysis were conducted on mice with c-Met overexpression (U87MG) and low expression (OVCAR3) tumor xenograft models (n=4 per group) after injection of approximately 7.4 MBq of 68Ga-NODAGA-C21b for up to 2 h after injection. Results 68Ga-NODAGA-C21b was successfully synthesized in high radiochemical purify (>99%) and yield (>98%) and demonstrated high stability in mouse serum for up to 2 h incubation. U87MG cells showed increased uptake of 68Ga-NODAGA-C21b tracer with longer incubation time (from 9.6 % at 15 min to 14.2 % at 2 h incubation). The uptake could be effectively reduced by excess unlabeled C21b and c-Met inhibitor Crizotinib (14.2 % vs. 2.4 % and 2.3 % for self-blocking and Crizotinib blocking, respectively, after 2 h incubation). Binding affinity assays revealed the Kd was 2.88 nM for U87MG cells. Small animal PET/CT imaging showed that 68Ga-NODAGA-C21b accumulated in U87MG tumor and retained at similar level during the 2 h monitoring (0.63, 0.46 and 0.45 %ID/g at 30, 60 and 120 min post injection). However, in OVCAR3 tumor, the signal was significantly lower from beginning and decreased dramatically afterwards (0.47, 0.26 and 0.20 %ID/g at 30, 60 and 120 min post injection). Biodistribution results exhibited that Tumor/Muscle (T/M) signal ratio increased from 3.18 to 4.15 in U87MG model at 2 h post injection time point while T/M ratio decreased from 2.29 to 1.66 in OVCAR3 model. And Tumor/Brain (T/B) signal ratio was higher in U87MG model than that of in OVCAR3 model at all three time points (2.53 vs. 1.56, 2.37 vs. 1.36 and 2.39 vs. 1.85). The probe was found to be mainly metabolized through liver and spleen. Conclusions c-Met targeted 68Ga-NODAGA-C21b is a novel small molecule based PET probe for imaging of c-Met overexpression tumors. Its ability to differentiate tumors with high and low c-Met expression in vivo holds the potential for stratification of patients for c-Met targeted cancer therapy. $$graphic_A6B47F64-40EB-4636-AEF2-5EF8FE968326$$

Pet Imaging of C-Met in Cancer with Cu-64-Labeled Hepatocyte Growth Factor

IDDF2024-ABS-0283 De Novo Discovery of C-Met—targeting Peptides for 68Ga-Pet Imaging of Hepatocellular Carcinoma

Sodium Pump Na Plus /K Plus ATPase Subunit 1-Targeted Positron Emission Tomography Imaging of Hepatocellular Carcinoma in Mouse Models

68Ga-Labeled Small Molecule Inhibitor for C-Met Targeted Pet Imaging of Tumor.

Development of a Novel 18F-Labeled Small Molecule Probe for PET Imaging of Mesenchymal Epithelial Transition Receptor Expression

Single Chain Antic-Met Antibody Conjugated Nanoparticles for in Vivo Tumor-Targeted Imaging and Drug Delivery

Synthesis and evaluation of 64 Cu-radiolabeled NOTA-cetuximab ( 64 Cu-NOTA-C225) for immuno-PET imaging of EGFR expression.

Small-Animal PET Imaging of Human Epidermal Growth Factor Receptor Positive Tumor with a 64cu Labeled Affibody Protein

Data from Anti-MET ImmunoPET for Non–Small Cell Lung Cancer Using Novel Fully Human Antibody Fragments

Synthesis and bioevaluation of a novel 99mTc-labeled complex with a crizotinib HYNIC derivative for imaging of c-Met–positive expression

Evaluation of 64cu Radiolabeled Anti-Hpd-l1 Nb6 for Positron Emission Tomography Imaging in Lung Cancer Tumor Mice Model

PET of follicle-stimulating hormone receptor: broad applicability to cancer imaging.

Synthesis and evaluation of 18F labeled crizotinib derivative [18F]FPC as a novel PET probe for imaging c-MET-positive NSCLC tumor

64 Cu-Labeled Affibody Molecules for Imaging of HER2 Expressing Tumors

Design and Bio.Evaluation of Cu-64-Nota-Herceptin for Tumor Targeted Micro-Pet Imaging

PET Imaging of Insulin-Like Growth Factor Type 1 Receptor Expression with a 64Cu-Labeled Affibody Molecule

Radiolabeling and Evaluation of (64)Cu-Dota-f56 Peptide Targeting Vascular Endothelial Growth Factor Receptor 1 in the Molecular Imaging of Gastric Cancer.

PET imaging of hepatocellular carcinoma by targeting tumor-associated endothelium using [68Ga]Ga-PSMA-617

PET imaging of a 68Ga labeled modified HER2 affibody in breast cancers: from xenografts to patients

PET imaging of CD105/endoglin expression with a 61/64 Cu-labeled Fab antibody fragment

PET imaging of EGFR expression in nude mice bearing MDA-MB-468, a human breast adenocarcinoma.